A Comparative Clinical Study of Tukhm-e-Hulba and Gilo in Dayabitus Shakri (Type 2 Diabetes Mellitus) with Control drug in its Management - NI

Dept Moalejat0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•Any one of these:
•Fasting blood sugar (FBS): 126mg/dl to 180mg/dl (or)
•Post Prandial blood sugar (PPBS): 200mg/dl to 250mg/dl (or)
•Glycated haemoglobin (HbA1C): 6.0% to 7.5%
•Patient willing to sign the written informed consent.
•Newly diagnosed patient of Type 2 Diabetes mellitus.
•Known case of Diabetes mellitus not taking any traditional or conventional treatment.
•Urine for microalbuminuria: A1 and A2
•Patient having BMI more than or equal to 18.5

•Patients below 30 years and above 60 years of age.
•Presence of any evidence suggestive of microvascular and macrovascular complications.
•Patients of Malnutrition related Diabetes mellitus (MRDM).
•Any co-morbid condition.
•Pregnant and lactating women.
•Patient who fail to give consent.
•Patient who fail to follow up.
•Mentally retarded person.
•Patient having uncontrolled hypertension.

发起方

Dept Moalejat